$RTX

Goldman Sachs Adjusts RTX Price Target to $208 From $206

Goldman Sachs raised its price target for RTX from $206 to $208, according to a report published on 10/22/2026. The change reflects the firm's updated outlook on the company's valuation and earnings potential. RTX's current stock price is around $191.60, with a slight negative percentage change.

Original reporting
Published Oct 22, 2026, 12:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RTX
Bullish
high confidence
Mentioned
$RTX
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$RTXBullishHigh
01

Why it matters

The upward revision signals confidence in RTX's near‑term earnings and market positioning.

02

Market read

Analyst target changes can prompt short‑term trading activity and influence sector sentiment.

03

What to watch

Potential supply‑chain constraints or defense budget cuts could offset the bullish signal.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Goldman Sachs issued a new price target for RTX based on its valuation and earnings outlook.

Company-level read

Ticker impact

$RTXBullishHigh confidence
Context

Goldman Sachs raised Raytheon Technologies' price target to $208 from $206, indicating a modest bullish outlook.

Expected impact

likely modest upside as the market prices in the higher target

Evidence & confidence

Analyst target lifts often lead to short‑term buying pressure, especially when the revision is recent.

Market effects

A higher target may lift sentiment in the aerospace & defense sector.

U.S. defense stocks could see modest gains.

Limited to investors tracking defense equities.

Counterpoint

Target raise is modest; price may already reflect the outlook, limiting upside.

Key entities

  • Raytheon Technologies

    U.S. aerospace and defense manufacturer (ticker RTX).

  • Goldman Sachs

    Investment bank providing the price target revision.

Related articles

$RTXMed

RTX CEO says Pentagon contracts will drive major expansion in missile production

RTX CEO Chris Calio announced $70B in Pentagon contracts for Raytheon, ensuring nearly a decade of demand visibility. The deals involve Tomahawk, AMRAAM, SM-6, and SM-3 IB missiles. RTX plans to increase production 2-4x over 7-10 years, investing in supply chain and equipment. CFO Neil Mitchill expects revenue and profit growth as costs are charged to programs, with full-rate production by 2030. The contracts include safeguards against budgetary changes and order volume shifts.

$LMTHighAI 8/10

Lockheed Martin Rises 9% as Record Backlog Lifts Outlook; RTX Gains 2%, Northrop Grumman Advances 3%

Lockheed Martin (LMT) rose 9% after reporting Q3 results that beat estimates, with revenue up 11% to $20.7B, EPS at $7.97, and a record $292B backlog. The company raised its 2026 outlook, expecting revenue of $80B-$82B and EPS of $30.35-$30.75. RTX (RTX) and Northrop Grumman (NOC) also gained, up 2% and 3% respectively, as defense stocks outperformed the broader market.

$RTXHighAI 9/10

RTX's Booming Defense Segment Lifts All Ships

RTX reported Q3 2026 revenues of $25B, up from $22.5B YoY, with $59B in new awards boosting its backlog to $340B. Defense segment saw significant growth, while Collins Aerospace and Pratt & Whitney also contributed. Adjusted earnings grew by $1B for the quarter and $1.9B YTD. RTX raised full-year guidance, targeting $97-97.5B in revenue and $7.65-7.75 in EPS.

$RTXHighAI 8/10

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq Composite and Russell 2000 led a three-day market rally, with Nasdaq up 2.14% and Russell 2000 up 2.36% for the week. The Dow and S&P 500 also gained over 1.2%. Several companies reported earnings, including RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group (Nasdaq: CME), M/I Homes (NYSE: MHO), and Lockheed Martin (NYSE: LMT). RTX reported $25.0B in Q3 sales and raised its full-year outlook. Abbott posted 14.5% sales growth. CME Group saw record Q3 revenue.